Paul Ellis Marik is a professor of medicine and serves as Chief, Division of Pulmonary and Critical Care Medicine at Eastern Virginia Medical School. His research interest include sepsis and tissue oxygenation. According to El Mundo, Marik is a physician who specializes in lungs. Wikipedia
Marik was lead author of a journal article on the efficacy of ivermectin as a COVID-19 treatment, which had been provisionally accepted for publication by a Frontiers Media journal in early 2021, but which was subsequently rejected on account of what the publisher said were “a series of strong, unsupported claims based on studies with insufficient statistical significance” meaning that the article did “not offer an objective [or] balanced scientific contribution to the evaluation of ivermectin as a potential treatment for COVID-19”.
In March 2021, Marik was reprimanded by the Virginia Board of Medicine and ordered to complete additional education in prescribing practices after it was found he had prescribed drugs, including phenobarbital, oxycodone, tramadol, alprazolam, and diazepam, to people who were not his patients.
Marik has written over 450 peer reviewed journal articles.
The FLCCC Physicians
Founding members / MATH+ and I-MASK+ developers
Paul E. Marik, M.D., FCCM, FCCP
- Endowed Professor of Medicine
- Chief, Div. of Pulmonary & Critical Care Medicine
- Eastern Virginia Medical School Norfolk, Virginia
- Curriculum Vitae – Dr. Paul E. Marik
Pierre Kory, M.D., M.P.A.
- Pulmonary and Critical Care Specialist
- President, Frontline COVID-19 Critical Care Alliance (FLCCC Alliance)
- Curriculum Vitae – Dr. Pierre Kory
- Twitter: @PierreKory
G. Umberto Meduri, M.D.
- Professor of Medicine
University of Tennessee Health Science Center
- Pulmonary, Critical Care & Sleep Medicine and Research Services
Memphis V.A. Medical Center
- Curriculum Vitae – Dr. G. Umberto Meduri
Joseph Varon, M.D., FCCP, FCCM
- Professor of Acute & Continuing Care
- Chief of Staff & Chief of Critical Care
- United Memorial Medical Center, Houston, Texas
- Curriculum Vitae – Dr. Joseph Varon
Jose Iglesias, D.O.
- Assoc. Prof., Hackensack Meridian School of Medicine at Seton Hall
- Dept. of Nephrology & Critical Care / Community Medical Center
- Dept. of Nephrology, Jersey Shore University Medical Center
- Neptune, New Jersey
- Curriculum Vitae – Dr. Jose Iglesias
Keith Berkowitz, M.D., M.B.A.
- Medical Director, Center for Balanced Health
- Voluntary Attending Physician, Lenox Hill Hosp. New York, New York
- Curriculum Vitae – Dr. Keith Berkowitz
Fred Wagshul, M.D.
- Pulmonologist & Med. Dir., Lung Center of America
- Clinical Instructor, Wright State University School of Medicine,
- Dayton, Ohio
- Curriculum Vitae – Dr. Fred Wagshul
Flávio A. Cadegiani, MD, MSc, Ph.D.
- Endocrinologist & Visiting Professor, Faculty of Floriano (FAESF), Brazil
- Founder, President & Medical Director – Corpometria Institute, Brazil
- Ad hoc consultant for the Brazilian Health Regulatory Agency (Anvisa)
- Consultant for Nat’l. Commission for Incorporation of New Technologies, Devices and Drugs, Brazilian Health System (SUS)
- Curriculum Vitae – Flávio A. Cadegiani
Scott Mitchell, MBChB
- Associate Specialist
- Emergency Department
- Princess Elizabeth Hospital
- States of Guernsey
Eivind H. Vinjevoll, M.D.
- Senior Consultant Anesthesiologist
- Intensive Care, Emergency Medicine, Anesthesia
- Volda, Norway
Frontiers Removes Controversial Ivermectin Paper Pre-Publication
A review article containing contested claims about the tropical medicine drug as a COVID-19 treatment was listed as “provisionally accepted” on the journal’s website before being removed this week.
Mar 2, 2021
he editors of Frontiers in Pharmacology have taken down an article about the use of the antiparasitic drug ivermectin in COVID-19 patients. The paper, which was written by members of an organization called the Front Line COVID-19 Critical Care Alliance (FLCCC), had been provisionally accepted and posted in abstract form by the journal in January, but was ultimately rejected this Monday (March 1). The editors determined that it contained unsubstantiated claims and violated the journal’s editorial policies.
By the end of last week, the abstract had been viewed more than 85,000 times, according to snapshots available on the internet archive.
The paper’s removal has drawn anger from members of the FLCCC and its followers. In comments on Twitter and in an interview with The Scientist, the organization’s president, Pierre Kory, describes the move as “censorship.” He adds in the interview that the paper had already successfully passed through multiple rounds of review. In reversing the paper’s acceptance, the journal is “allowing some sort of external peer reviewer to comment on our paper,” he says. “I find that very abnormal.”
Ivermectin is widely used in tropical medicine to treat parasitic infections, but its use as a COVID-19 drug has been controversial since the beginning of the pandemic, with major health organizations consistently stating that there is insufficient evidence for its efficacy in prevention or treatment of the disease.
The FLCCC’s paper (also posted on the organization’s website) reviewed epidemiological and clinical evidence on ivermectin’s use in people infected with and exposed to SARS-CoV-2. In it, the authors argued that health agencies such as the National Institutes of Health (NIH) should update their recommendations to include the drug.
After being contacted by The Scientist, the journal posted a statement from Frontiers’s chief executive editor, Frederick Fenter, saying that “Frontiers takes no position on the efficacy of ivermectin as a treatment of patients with COVID-19, however, we do take a very firm stance against unbalanced or unsupported scientific conclusions.”
During review of the article in what the journal refers to as “the provisional acceptance phase,” Fenter says in the statement, members of Frontiers’s research integrity team identified “a series of strong, unsupported claims based on studies with insufficient statistical significance, and at times, without the use of control groups.”
The statement continues: “Further, the authors promoted their own specific ivermectin-based treatment which is inappropriate for a review article and against our editorial policies. In our view, this paper does not offer an objective nor balanced scientific contribution to the evaluation of ivermectin as a potential treatment for COVID-19.”
The statement provided no information about why these concerns had been raised and acted on now, rather than earlier in the publication process.
This isn’t the first time that Kory and his colleagues at FLCCC have been accused of making unsubstantiated claims about ivermectin. In December, Kory gave a statement at a US Senate hearing on COVID-19 treatments in which he called ivermectin “effectively a ‘miracle drug’” that could obliterate disease transmission and prevent illness—claims that Associated Press fact-checkers labelled “False” at the time. Kory, who formerly oversaw critical care at the UW Health in Wisconsin, tells The Scientist that he now regrets using “miracle” and other hyperbolic terminology.
Later in December, FLCCC founder Paul Marik, the first author on the now-rejected Frontiers manuscript and a professor at Eastern Virginia Medical School, wrote a paper reviewing ivermectin that included references to debunked papers, including an observational study of ivermectin in COVID-19 patients led by now-discredited Surgisphere Corporation. That study, which had been posted on the preprint server SSRN, was taken down at the request of one of the authors back in May after concerns were raised about the provenance of the company’s data.
Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19
Kory, Pierre MD1,*; Meduri, Gianfranco Umberto MD2; Varon, Joseph MD3; Iglesias, Jose DO4; Marik, Paul E. MD5Author Information American Journal of Therapeutics: May/June 2021 – Volume 28 – Issue 3 – p e299-e318 doi: 10.1097/MJT.0000000000001377